Canaccord Genuity Gives Buy Rating to Watson Pharmaceuticals Incorporated (WPI)

By admin | 6 years ago

Watson Pharmaceuticals Incorporated (NYSE: WPI)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a report issued on Tuesday.

Shares of Watson Pharmaceuticals Incorporated opened at 71.00 on Tuesday. Watson Pharmaceuticals Incorporated has a 52 week low of $55.00 and a 52 week high of $76.47. The company has a market cap of $9.046 billion and a P/E ratio of 33.36.

Watson Pharmaceuticals Incorporated last announced its earnings results on Monday, April 30th. The company reported $1.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.04. The company’s revenue for the quarter was up 73.9% on a year-over-year basis. On average, analysts predict that Watson Pharmaceuticals Incorporated will post $1.34 earnings per share next quarter.

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Tuesday, May 1st. They now have a $79.00 price target on the stock. Separately, analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Watson Pharmaceuticals Incorporated from $60.00 to $81.00 in a research note to investors on Tuesday, May 1st. They now have a “hold” rating on the stock. Finally, analysts at Bank of America (NYSE: BAC) raised their price target on shares of Watson Pharmaceuticals Incorporated from $72.00 to $92.00 in a research note to investors on Friday, April 27th. They now have a “buy” rating on the stock.

Watson Pharmaceuticals, Inc. (Watson) is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products.

About the author